EFM
CRSP icon

E Fund Management’s CRISPR Therapeutics CRSP Stock Holding History

E Fund Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$449K Sell
8,239
-3,372
-29% -$178K 0.01% 298
2026
Q1 		$552K Buy
+11,611
New +$612K 0.02% 274
2025
Q2 		$621K Sell
12,764
-884
-6% -$34.2K 0.03% 206
2025
Q1 		$464K Buy
13,648
+1,863
+16% +$79K 0.02% 236
2024
Q4 		$464K Sell
11,785
-1,951
-14% -$92.1K 0.02% 237
2024
Q3 		$645K Buy
13,736
+2,648
+24% +$134K 0.03% 174
2024
Q2 		$599K Buy
11,088
+5,597
+102% +$324K 0.03% 162
2024
Q1 		$374K Sell
5,491
-3,969
-42% -$284K 0.02% 240
2023
Q4 		$592K Buy
9,460
+303
+3% +$16.8K 0.04% 131
2023
Q3 		$416K Buy
9,157
+1,863
+26% +$96.2K 0.03% 164
2023
Q2 		$409K Sell
7,294
-1,642
-18% -$93.2K 0.03% 162
2023
Q1 		$404K Buy
8,936
+308
+4% +$15K 0.03% 163
2022
Q4 		$351K Buy
8,628
+1,515
+21% +$80.4K 0.03% 207
2022
Q3 		$465K Buy
7,113
+245
+4% +$17.8K 0.04% 135
2022
Q2 		$417K Buy
+6,868
New +$404K 0.04% 182

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

E Fund Management's CRSP Position: Q2 2026 in Review

E Fund Management reduced its CRISPR Therapeutics (CRSP) stake by 29% in Q2 2026, selling an estimated $178K and leaving 8,239 shares worth $449K. The position accounts for 0.01% of the portfolio, ranked #298.

E Fund Management first reported a position in CRSP in Q2 2022 and has held it in 15 quarters since. The position peaked at $645K in Q3 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • E Fund Management held 8,239 shares of CRISPR Therapeutics worth $449K as of Q2 2026.
  • E Fund Management sold 3,372 CRISPR Therapeutics shares in Q2 2026, an estimated $178K.
  • CRISPR Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #298 holding.
  • E Fund Management first reported a position in CRISPR Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • E Fund Management's CRISPR Therapeutics position peaked at $645K in Q3 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.